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The marker strategy design (MSGD) has been proposed to assess and validate predictive
markers for targeted therapies and immunotherapies. Under this design, patients are ran-
domized into two strategies: the marker-based strategy, which treats patients based on their
marker status, and the non-marker-based strategy, which randomizes patients into treat-
ments independent of their marker status in the same way as in a standard randomized
clinical trial. The strategy effect is then tested by comparing the response rate between the
two strategies and this strategy effect is commonly used to evaluate the predictive capability
of the markers. We show that this commonly used between-strategy test is flawed, which
may cause investigators to miss the opportunity to discover important predictive markers or
falsely claim an irrelevant marker as predictive. Then we propose new procedures to improve
the power of the MSGD to detect the predictive marker effect. One is based on a binary
response endpoint; the second is based on survival endpoints. We conduct simulation stud-
ies to compare the performance of the MSGD with the widely used marker stratified design
(MSFD). Numerical studies show that the MSGD and MSFD has comparable performance.
Hence, contrary to popular belief that the MSGD is an inferior design compared with the
MSFD, we conclude that using the MSGD with the proposed tests is an efficient and ethical
way to find predictive markers for targeted therapies.
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1 Introduction
The emergence of immunotherapy and targeted therapy has revolutionized the era of clinical
oncology1,2. One of the biggest challenges of immunotherapy is that it typically benefits
only a subgroup of patients.3 As a result, optimizing the treatment benefit of immunother-
apy requires the identification of the predictive biomarker that can be used to foretell the
differential efficacy of the immunotherapy based on the presence or absence of the marker,
e.g., pembrolizumab is approved by the Food and Drug Administration for the treatment of
advanced melanoma and metastatic squamous and nonsquamous non-small cell lung cancer
(NSCLC) whose tumors express programmed death ligand-1 (PD-L1), i.e., PD-L1 positive
patients.
Several novel biomarker-guided clinical trial designs have been proposed to achieve this
goal4,5,6,7,8,9,10. Among them, the marker strategy design (MSGD) has been proposed as a
useful trial design for identifying and validating predictive markers4,5,6. As shown in part
(a) of Figure 1, the MSGD randomizes patients to two strategies, namely, the marker-based
strategy and the non-marker-based strategy. Patients randomized to the marker-based strat-
egy are treated (deterministically) based upon their biomarker statuses (e.g., patients with
a marker-positive status receive the targeted treatment and those with a marker-negative
status receive the standard treatment). Patients randomized to the non-marker-based strat-
egy are further randomized to different treatments independent of their marker statuses.
Although measuring the biomarker profiles of patients randomized to the non-marker-based
strategy is not required, in practice we often do so, prospectively or retrospectively, for the
purpose of biomarker discovery and other correlation studies. In this article, we assume that
the biomarker is measured for all patients in the trial. A series of clinical trials11,12,13 has
adopted the MSGD for evaluating and validating predictive marker effects. For example,
by using the MSGD, the excision repair cross-complementing 1 (ERCC1) trial11 found that
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the ERCC1 mRNA expression level might be a predictive marker for treating non-small cell
lung cancer (NSCLC) patients with docetaxle plus gemcitabine (the p-value = 0.02) based
on 444 patients with stage-IV NSCLC.
In addition to the MSGD, another biomarker-guided clinical trial design which has been
widely used to identify and validate the predictive marker is the marker stratified design
(MSFD)4,5,6. As shown in part (b) of Figure 1, the MSFD stratifies patients into different
subgroups based on the patients’ biomarker profile and then randomizes the patients to
receive either the targeted treatment or the standard treatment within each subgroup. Under
the MSFD, the predictive biomarker effect is typically evaluated by comparing the difference
in the treatment effects within the marker-positive subgroup to those within the marker-
negative subgroup14. Under the MSGD, however, the most common approach to test the
predictive marker is to compare the response rate (or hazard for survival outcome) between
the marker-based and non-marker-based strategies using a t test (or log-rank test). If the
response rate of the marker-based strategy is significantly higher than that of the non-
marker-based strategy, the marker is claimed as the predictive marker. Mandrekar and
Sargent5 and Freidlin et al.15 noted that the between-strategy test has low statistical power
to detect the predictive biomarker effect because a certain proportion of patients will receive
the same treatment regardless of their assignment to the marker-based or non-marker-based
strategies (e.g., some patients with a marker-positive status in both strategies will receive the
targeted treatment), thereby diluting the differences between the two treatment strategies.
Therefore, it is generally believed that the MSGD design is an inferior design compared with
the MSFD15.
In this article, we argue that the primary interest of MSGD is to evaluate the between-
strategy effect, which does not necessarily equal to the predictive effect defined in the MSFD.
Therefore, it is unfair to directly compare MSGD with MSFD as these two designs target
for different objects. Actually, if the predictive marker effect rather than the between-
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strategy effect is the primary interest of a clinical trial, we prove in the following content
that the commonly used between-strategy test by MSGD is indeed problematic. After that,
we propose a new test to evaluate the true predictive marker effect under MSGD. Finally,
we conduct simulation studies to compare MSGD with MSFD under the same definition of
predictive marker. Our simulation results reveal that contrary to popular belief, the MSGD
is not an inferior design and has plausible performance compared with the MSFD.
Our study is motivated by a colorectal cancer trial, which is being conducted at the
Indiana University Melvin and Bren Simon Cancer Center. The biomarker used in this trial is
the KRAS gene mutation. The MTA is a novel KRAS inhibitor and the standard treatment is
radiotherapy. This trial is conducted under the MSGD. A total of 210 patients with colorectal
cancer are equally randomized to either the non-marker-based strategy and marker-based
strategy. Patients in the non-marker-based strategy are further equally randomized to receive
either the MTA or the standard treatment. Patients in the marker-based strategy are treated
according to their KRAS gene status. The patients without the KRAS gene mutation receive
the standard treatment whereas the patients with the KRAS gene mutation receive the MTA.
The purpose of this trial is to evaluate whether the KRAS gene is a predictive marker for
patients with colorectal cancer. As the commonly used between-strategy test is problematic
in detecting the predictive effect, novel test is required to evaluate such effect, which inspires
the research for this article.
2 Deficiency of the between-strategy test
We first use two numerical examples to illustrate that the between-strategy test adopted
by the MSGD is fundamentally flawed to detect the predictive marker effect. Suppose that
the patient population of interest consists of 20% marker-positive (M+) patients and 80%
marker-negative (M−) patients. Assume that for the standard treatment, the response
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rates for the M+ and M− patients are the same, at a value of 0.4; and for the targeted
treatment under investigation, the response rates for the M+ and M− patients are 0.8
and 0.5, respectively. Clearly, M is a predictive marker because the M+ patients respond
to the targeted treatment substantially more favorably than the M− patients. Now, we
look at the response rate in the marker-based strategy and the non-marker-based strategy.
As summarized in Table 1, in the marker-based strategy, M+ patients are assigned to the
targeted treatment, and M− patients are assigned to the standard treatment. Thus, the
overall average response rate for the marker-based strategy is 20%× 0.8 + 80%× 0.4 = 0.48.
In the non-marker-based strategy, patients are equally randomized into the standard and
targeted treatments. The average response rate is (0.8 + 0.4)/2 = 0.6 for the M+ patients,
and (0.5 + 0.4)/2 = 0.45 for the M− patients. Thus, the overall average response rate for
the non-marker-based strategy treatment arm is 20% × 0.6 + 80% × 0.45 = 0.48, which is
the same as that of the marker-based strategy! This means that we will completely miss
the predictive marker effect if we take the approach of the commonly used between-strategy
test.
The between-strategy test can also mislead investigators to falsely conclude that a marker
is predictive when it actually is not. To see this, consider a case similar to the above example,
but now the marker is not predictive, with the response rate of the targeted treatment being
the same (0.1) for both the M+ and M− patients. In this case, as shown in Table 1, the
overall average response rate in the marker-based strategy is 0.34, higher than the overall
response rate in the non-marker-based strategy (i.e., 0.25). If we use the between-strategy
test, we will draw an incorrect conclusion that the marker is predictive.
Mathematically, the deficiency of the between-strategy test stems from the fact that the
treatment effect evaluated by the between-strategy test is actually not the predictive marker
effect, except under certain restrictive conditions, as described in Theorem 1. The proof is
provided in Appendix.
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Theorem 1 Let φ be the marker positive prevalence. For the binary endpoint, the between-
strategy Z test is valid for testing the predictive marker effect only when φ = 0.5; and for the
time-to-event endpoint, the between-strategy log-rank test is valid for testing the predictive
marker effect only when (1) there is no treatment effect or (2) there is no prognostic effect
and φ = 0.5.
3 New tests for detecting the predictive marker effect
3.1 Binary endpoint
In this section, we describe new procedures that are generally valid for the MSGD to detect
the predictive marker effect. We first consider the binary response outcome. Let pjk denote
the response rate for patients with marker status k who are receiving treatment j, where
k = +/− denotes marker-positive/-negative, and j = 1/0 denotes the targeted/standard
treatment. The treatment effects of the targeted agent (with respect to the standard treat-
ment as a control) are given by p1+−p0+ and p1−−p0− for M+ and M− patients, respectively.
The predictive marker effect is defined as θ = (p1+ − p0+)− (p1− − p0−), i.e., the difference
in the treatment effect between M+ and M− patients, with θ = 0 representing that the
marker is not predictive. We notice that this definition has also been used by the MSFD to
define the predictive marker effect4,14. Our goal here is to test H0 : θ = 0 versus H1 : θ 6= 0.
We also aware that the definition of the predictive marker effect is not unique. Indeed, the
predictive marker effect can also be defined as a treatment-marker interaction term in a
logistic model16,17, which is beyond the scope of this article.
Let p̂jk = mjk/njk denote the observed response rate for patients with marker status k
who are receiving treatment j, where njk is the number of patients having marker status k
who are receiving treatment j, and mjk is the number of responses among njk patients. We
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propose to evaluate the predictive marker effect for the MSGD using the following Z test,
Z =










which asymptotically follows a standard normal distribution under the null that there is no
predictive marker effect. Given a significance level of α, we declare that M is a predictive
marker if |Z| > zα/2, where zα/2 is the upper α/2 quantile of a standard normal distribution.
It can be shown that under the alternative hypothesis H1 : θ = θ1, Z asymptotically





3φp1+(1− p1+) + φp0+(1− p0+) + (1− φ)p1−(1− p1−) + 3(1− φ)p0−(1− p0−)
.
Given the type I error α, the power of the test under H1 is given by
Pr(|Z| > |Φ−1(α/2)|) = Pr(Z > −Φ−1(α/2)) + Pr(Z < Φ−1(α/2))
= Φ(Φ−1(α/2) + |τ |) + Φ(Φ−1(α/2)− |τ |)
≈ Φ(Φ−1(α/2) + |τ |).
Hence, to achieve the power of 1 − β, we require Φ−1(α/2) + |τ | = Φ−1(1 − β), leading to




[Φ−1(1− β)− Φ−1(α/2)]2[3φp1+(1− p1+) +
φp0+(1− p0+) + (1− φ)p1−(1− p1−) + 3(1− φ)p0−(1− p0−)].
As most sample size calculations, the value of n depends on a variety of parameters, such
as p1+, p1−, p0+ and p0−. The values of these parameters can be estimated from historical
data or provided by investigators based on their domain knowledge. If such prior information
is not available, a pilot study may be needed to obtain initial estimates of the parameters.
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3.2 Survival endpoint
We now turn to the survival endpoints (e.g., progression-free survival or overall survival). Let
λjk denote the hazard rate for the patients with D = j and M = k, and θ+ = log(λ1+/λ0+)
and θ− = log(λ1−/λ0−) denote the log hazard ratio between the targeted treatment and
standard treatment for the M+ patients and M− patients, respectively. That is, θ+ and θ−
respectively represent the treatment effect of the targeted agent (with respect to the standard
treatment as the control) for the M+ patients and M− patients. Then, the predictive marker
effect can be defined as θ = θ+ − θ−, with θ = 0 representing no predictive marker effect.
We are interested in testing H0 : θ = 0 versus H1 : θ 6= 0.
Let Z̃+ and Z̃− denote the standard log-rank test statistics of comparing the targeted
treatment versus the standard treatment for M+ and M− patients, respectively; and let φ
denote the prevalence of M+ patients. We propose to test the predictive marker effect using






The asymptotic distribution of Z̃ is described in Theorem 2. The proof is provided in
Appendix.
Theorem 2 Let ∆ be the total number of events. Test statistic Z̃ asymptotically follows





under H1 : θ = θ1.
Along the same line as the binary endpoint, given the type I error α and type II error β,





Under the MSGD, patients are randomized into two strategies. As a result, the between-
strategy comparison is free of the influence of unmeasured confounders because the effects
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of the confounders are balanced out between the two strategies through randomization. One
may be concerned as to whether the proposed tests are subject to the influence of unmeasured
confounders. The result is described in Theorem 3.
Theorem 3 The proposed tests are free from the influence of unmeasured confounders,
and thus the predictive marker effect evaluated by the proposed tests is a causal effect.
The proof of Theorem 3 is provided in the Appendix.
4 Simulation Study
We carried out simulation studies to compare the performance of the proposed approaches
with the commonly used between-strategy test under the MSGD. We considered three cases:
(1) the marker has no predictive effect, which corresponds to the null scenario of no predictive
marker effect; (2) the marker has only the predictive effect; and (3) the marker has both
predictive and prognostic effects. The prognostic effect is a type of marker effect that is not
affected by the treatment, e.g., tumor stage is often a prognostic marker, and patients with
higher stages have poor outcomes, regardless of the treatment. Our purpose of the simulation
was to evaluate the predictive marker effect only. Hence, case (1) was used to evaluate the
empirical type I error rate, and cases (2) and (3) were used to evaluate the empirical power.
Under each of the simulation configurations, we conducted 10,000 simulated trials to evaluate
the type I error rate and power, with a nominal level of 5%.
Table 2 shows the results for the binary response outcome. The between-strategy test
generally led to inflated type I error rates except when φ = 0.5. For example, when φ = 0.3,
the response rate of the standard treatment is 0.1 for M+ and M− patients, the response
rate of the targeted treatment is 0.4 for M+ and M− patients, and the type I error rate
was inflated to 17.8%. In contrast, the proposed Wald test consistently yielded type I error
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rates around the nominal level of 5%. In terms of power, the proposed test significantly
outperformed the between-strategy test. The power gain ranged from 30% to 50%, depending
on the size of the predictive marker effect. For example, when the true response rate of the
standard treatment is 0.2 for M+ and M− patients and the true response rates of the
targeted treatment are 0.6 and 0.1 for M+ and M− patients, given that the prevalence of
the M+ status is 30%, the power of the proposed test is 88.8%, while that of the between-
strategy test is merely 33.5%.
Table 3 shows the results for the survival endpoint. We use the exponential distribution
to generate the survival endpoint and specify a 20% censoring rate for each patient. The
simulation results for the survival endpoint were similar to those for the binary outcomes.
That is, the between-strategy test inflated the type I error rate except when the M+ preva-
lence was φ = 0.5, while the proposed test consistently yielded reasonable type I error rates
close to the nominal value of 5%. Compared to the between-strategy comparison, the power
of the MSGD often more than doubled when using the proposed test.
In addition to the MSGD, the MSFD can also be used to evaluate the predictive marker
effect and it is popular belief that MSFD is much more powerful than the MSGD. However,
we argue that such conclusion is arbitrary because the original MSGD actually evaluate
the between-strategy effect. Therefore, to make a fair comparison, we conducted simulation
studies to compare the MSGD with MSFD by using the same test proposed in this paper.
That is, both designs were targeted for the same predictive marker effect. Also, the between-
strategy test was also used for the MSGD for the purpose of power comparison. In addition
to the power evaluation, we also reported the number of response (for the binary response)
and the median survival month (for the survival outcome) to investigate the individual ethics
of these two designs.
Table 4 summarizes the simulation results for the binary response outcome. In terms
of power comparison, the MSGD is less powerful mainly because the between-strategy test
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used. For example, given φ = 0.3 and n = 200, when the true response rate of the standard
treatment is 0.2 for M+ and M− patients and the true response rates of the targeted
treatment are 0.4 and 0.1 for M+ and M− patients, if the between-strategy test is used,
the MSGD is 42.9% less powerful than the MSFD. On the other hand, if the proposed
test is used, then the MSGD is only 7% less powerful. Moreover, although the MSGD was
still 5% to 10% less powerful than the MSFD with the proposed method, this design gets
around 6 to 12 more patients response to the treatment, indicting the MSGD a more ethical
design. This is because the MSGD allocates patients to more effective treatments based on
their biomarker profiles in the marker-based strategy arm, thereby enhancing the ethics of
the trial. As a tradeoff, the randomization in the MSGD is less balanced than the MSFD,
resulting in a slight power loss. The simulation results in Table 5 for the survival outcome
were similar to those in Table 4. When the proposed method is used, the MSGD was only
slightly less powerful than the MSFD, but the median survival month for the MSGD was 2
to 10 months longer. Hence, these two designs yield comparable performance and the MSGD
is particularly useful when the predictive marker effect is large. That is because, with a large
effect size, both the MSGD and MSFD should be able to identify the predictive marker but
the MSGD can benefit more patients enrolled in the trial.
As a side note, our results also indicate that the criticism that the MSGD is an inefficient
design with low power to detect predictive markers5,15 is not completely valid. Low statistical
power is not an inherent deficiency of the MSGD design itself, but simply caused by the
use of an inappropriate statistical method (i.e., between-strategy test). When adopting the




The MSGD has been used in clinical trials to evaluate predictive marker effects. In this arti-
cle, we show that, under the MSGD, the commonly used between-strategy test for assessing
the predictive marker effect is fundamentally flawed. Such an approach not only suffers from
low statistical power, but also potentially misleading results, e.g., falsely declaring that a
marker is predictive when it is actually not. We propose new tests to be used with the
MSGD for detecting the predictive marker effects. Numerical studies show that the pro-
posed tests are generally valid and substantially more powerful than the between-strategy
tests. Equipping the MSGD with the proposed tests provides clinicians a powerful design to
detect predictive marker effects. Our simulation results also show that compared with the
MSFD, the true power reduction by using the MSGD is at most 10% but the MSGD is a
more ethical design. Therefore, we conclude that the MSGD is not an inferior design and is
especially useful when the predictive marker effect is large. The choice between the MSFD
and MSGD depends on the trial setting and objectives. If power is of the biggest concern, the
MSFD might be preferred. If investigators are interested in evaluating the real-world effect
of the targeted therapy (i.e., the benefit of personalizing treatment by patient’s biomarkers
versus treating patients without using their biomarkers), the MSGD is clearly the choice.
In addition, as the personalized treatment component of the MSGD may increase patient
enrollment and retention, the MSGD is an attractive option when patient accrual is difficult,
in particular given that the power loss of the MSGD is generally minor.
We have focused on the case in which the marker is measured for all patients prospectively
or retrospectively. In principle, the MSGD does not require the measurement of the marker
for the patients randomized to the non-marker-based strategy. If this is the case, we can
extend our methods to accommodate the missing marker information, for example, using
the expectation-maximum algorithm. These extensions are statistically more involved and
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will be discussed elsewhere.
In conclusion, on the basis of the results of our study, the common approach of using
the between-strategy test to detect predictive markers is problematic and has caused the
misconception that the MSGD is an inefficient design with low statistical power. By using
the proposed testing procedures, the MSGD provides a powerful and ethical clinical trial
design to detect predictive markers.
Appendix
(A) Proof of Theorem 1
We consider the binary endpoint first. For the equally randomized MSGD, the response
rate for the marker-based strategy is p1+φ + p0−(1 − φ) and the response rate for the non-
marker-based strategy is 0.5[(p1+ + p0+)φ + (p1− + p0−)(1 − φ)]. Hence, defining θ∗ as the
between-strategy difference, it can be expressed as θ∗ = 0.5[(1−φ)θ+(2φ−1)(p11−p01)] and
the conventional between-strategy method indeed tests the hypothesis H0 : θ
∗ = 0 versus
H1 : θ
∗ 6= 0, since in general we have p11 6= p01. As a result, when θ = 0, θ∗ = 0 only if
φ = 0.5. That is, the between-strategy test is statistically valid only when the restrictive
condition φ = 0.5 holds.
Similarly, for the survival endpoint, the hazard ratio at time t under the marker-based
strategy is
λ00e
−λ00t(1− φ) + λ11e−λ11tφ
e−λ00t(1− φ) + e−λ11tφ
and the hazard ratio at time t under the non-marker-based strategy is
0.5λ00e
−λ00t(1− φ) + 0.5λ01e−λ01tφ+ 0.5λ10e−λ10t(1− φ) + 0.5λ11e−λ11tφ
0.5e−λ00t(1− φ) + 0.5e−λ01tφ+ 0.5e−λ10t(1− φ) + 0.5e−λ11tφ
.
When θ = 0, these two hazard ratios are equivalent only if (1) there is no treatment effect
or (2) there is no prognostic effect and φ = 0.5. Therefore, for the survival endpoints, the
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between-strategy test is valid to detect the predictive marker effect only if one of these two
restrictive conditions hold.
(B) Proof of Theorem 2
For the survival endpoint, defining ∆ as the total number of events, according to Schoen-












φZ̃− has the following asymptotic distribution
Z̃ ∼ N(
√
3(1− φ)φ∆(θ+ − θ1)
4











(C) Proof of Theorem 3
Note that the predictive marker effect θ = (p1+ − p0+) − (p1− − p0−), where (p1+ − p0+)
and (p1+− p0+) are respectively the treatment effects of the targeted treatment for the M+
and M−patients, with respect to the standard treatment as a control. In order to show
that θ is free of the influence of unmeasured confounders, we just need to show that both
(p1+ − p0+) and (p1− − p0−) are free of the influence of unmeasured confounders. We first
look at (p1+ − p0+). Because patients are randomized into two strategies, the M+ patients
assigned to the marker-based strategy (denoted as P1) should be comparable to the M+
patients assigned to the non-marker-based strategy (denoted as P0) in the sense that all
unmeasured confounders are balanced between P1 and P0. We use P1 ∼ P0 to denote
that P1 and P0 are comparable. In the non-marker-based strategy, patients are further
randomized into the targeted treatment and standard treatment. That is, P0 is further
randomized into the targeted treatment and standard treatment, denoted as P0t and P0s,
respectively, with P0t ∪ P0s = P0. Because of randomization, P0t ∼ P0s ∼ P0. Because
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P1 ∼ P0, it follows that P0t∪P1 ∼ P0s. As a result, the comparison of the response between
the targeted and standard treatments based on P0t ∪ P1 (i.e., M+ patients received the
targeted treatment) versus P0s (i.e., M+ patients received the standard treatment), i.e.,
(p̂1+ − p̂0+), is free from the influence of unmeasured confounders. By the same argument,
the comparison of the response between the targeted and standard treatments based on M−
patients, i.e., (p̂1− − p̂0−), is also free from the influence of unmeasured confounders. Thus,
the proposed Z test is free from the influence of unmeasured confounders. Along the same
line, it follows that the proposed weighted log-rank test is also free from the influence of
unmeasured confounders.
Acknowledgments
The authors thank three referees for their valuable comments. The research of Yong Zang
is partial supported by the design and biostatistics program pilot grant, Indiana CTSI and
NIH P30 grant CA082709. The research of Muyi Li is partial supported by the NSFC (No.
71671150) and Fujian Key Laboratory of Statistical Science.
15
Table 1: Examples to illustrate the deficiency of the between-strategy test.
Example 1: marker is predictive Example 2: marker is not predictive
Marker-based strategy Non-marker-based strategy Marker-based strategy Non-marker-based strategy
Treatment M+ (20%) M- (80%) M+ (20%) M- (80%) M+ (20%) M- (80%) M+ (20%) M- (80%)
Targeted 0.8 N/A 0.8 0.5 0.1 N/A 0.1 0.1
Standard N/A 0.4 0.4 0.4 N/A 0.4 0.4 0.4
Average 0.8 0.4 0.6 0.45 0.1 0.4 0.25 0.25
Overall 0.48 0.48 0.34 0.25
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Table 2: Type I error rate and power (%) of the MSGD for evaluating the predictive marker
effect under the proposed approach (pro.) and between-strategy (str.) comparison when the
outcome is a binary response endpoint and n = 200.
True response rate Prevalence of M+
Standard Targeted 30% 50% 70% 45% 55%
M+ M- M+ M- str. pro. str. pro. str. pro. str. pro. str. pro.
No predictive (type I error rate)
0.1 0.1 0.2 0.2 7.2 4.9 5.3 5.1 7.3 5.1 5.5 5.2 5.2 4.9
0.1 0.1 0.3 0.3 11.6 5.2 5.4 5.1 10.9 5.2 5.5 5.1 5.9 5.3
0.1 0.1 0.4 0.4 17.8 4.8 5.2 4.9 15.9 5.3 6.0 5.0 6.0 5.3
Predictive only (power)
0.2 0.2 0.4 0.1 20.1 52.1 23.3 63.3 26.7 58.4 22.3 61.1 24.0 62.6
0.2 0.2 0.5 0.1 26.7 73.8 35.2 83.8 43.7 80.6 33.2 83.1 36.3 84.4
0.2 0.2 0.6 0.1 33.5 88.8 46.9 95.2 62.4 92.4 43.5 94.6 50.9 95.4
0.2 0.2 0.7 0.1 40.1 95.9 60.4 98.9 77.8 98.1 55.1 98.9 64.2 99.1
Predictive + prognostic (power)
0.2 0.4 0.3 0.1 46.7 74.4 34.5 83.5 23.4 76.8 37.7 81.7 32.4 82.7
0.2 0.4 0.4 0.1 52.9 88.1 47.1 94.3 41.2 90.6 48.9 93.7 45.8 94.6
0.2 0.4 0.5 0.1 61.1 95.7 59.3 98.7 58.8 97.1 60.1 98.6 58.8 98.5
0.2 0.4 0.6 0.1 68.9 98.9 72.0 99.8 75.9 99.3 70.7 99.6 73.2 99.7
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Table 3: Type I error rate and power (%) of the MSGD for evaluating the predictive marker
effect under the proposed approach (pro.) and between-strategy (str.) comparison when the
outcome is a survival endpoint and n = 200.
True hazard Prevalence of M+
Standard Targeted 30% 50% 70% 45% 55%
M+ M- M+ M- str. pro. str. pro. str. pro. str. pro. str. pro.
No predictive (type I error rate)
0.5 0.5 0.25 0.25 13.7 4.7 4.8 4.6 12.7 5.3 4.9 4.5 5.5 5.3
0.5 0.5 0.15 0.15 26.1 5.0 5.0 5.1 22.4 5.2 6.1 4.8 5.8 4.5
0.3 0.3 0.10 0.10 26.7 5.4 5.4 5.2 17.5 4.9 6.2 4.5 6.6 5.3
Predictive only (power)
0.5 0.5 0.38 0.75 17.9 41.4 17.4 49.0 13.8 42.3 15.7 48.1 16.3 46.4
0.5 0.5 0.25 0.75 24.1 79.7 35.0 87.5 35.5 78.6 30.7 85.2 31.3 85.7
0.5 0.5 0.19 0.75 32.1 93.1 42.8 96.8 51.2 93.2 41.0 96.5 47.6 96.0
0.5 0.5 0.15 0.75 38.9 98.0 48.2 99.2 62.1 97.6 48.0 99.1 54.9 99.3
Predictive + prognostic (power)
0.5 0.4 0.36 0.60 21.6 46.2 20.3 53.2 17.6 43.0 20.0 50.9 20.0 52.4
0.5 0.4 0.30 0.60 22.0 65.5 23.8 73.0 27.5 62.2 27.4 70.1 27.1 70.9
0.5 0.4 0.24 0.60 28.8 79.2 35.8 89.1 44.2 81.7 34.3 89.5 37.3 86.3
0.5 0.4 0.16 0.60 39.2 96.6 50.0 99.3 58.2 96.7 45.4 98.8 52.6 98.6
18
Table 4: Type I error rate, power (%) and the number of response (in brackets) of the MSGD
and MSFD for evaluating the predictive marker effect under the between-strategy test and
proposed test when the outcome is a binary response endpoint.
True response rate Prevalence of M+
Standard Targeted 30% 50% 70%
M+ M- M+ M- MSGD MSFD MSGD MSFD MSGD MSFD
strategy proposed strategy proposed strategy proposed
n=200, No predictive
0.3 0.2 0.4 0.3 7.3 5.2(56.0) 5.2(54.0) 5.0 5.3(60.1) 5.1(59.9) 7.4 4.9(65.9) 5.0(63.9)
n=200, Predictive only
0.2 0.2 0.4 0.1 19.4 55.3(45.5) 62.3(38.9) 23.4 62.5(52.5) 73.7(45.0) 25.9 57.9(59.6) 70.7(51.0)
0.2 0.2 0.5 0.1 27.2 73.8(49.9) 83.6(41.8) 34.6 83.4(60.2) 93.1(50.0) 44.9 80.2(70.0) 91.5(58.0)
0.2 0.2 0.6 0.1 33.2 88.1(54.4) 95.5(44.9) 47.6 95.2(67.5) 98.9(54.9) 61.9 93.0(80.4) 98.4(64.9)
n=200, Predictive + prognostic
0.4 0.2 0.6 0.1 17.9 44.2(57.5) 57.3(51.1) 20.0 56.5(72.4) 68.2(64.9) 24.1 54.7(87.5) 66.2(78.9)
0.4 0.2 0.7 0.1 23.7 67.6(62.0) 81.3(53.9) 30.9 80.0(80.0) 91.3(69.9) 40.4 77.3(98.1) 90.3(86.0)
0.4 0.2 0.8 0.1 30.3 86.2(66.5) 95.8(57.0) 43.2 94.4(87.5) 98.8(74.9) 60.5 91.6(108.6) 98.4(92.8)
n=100, No predictive
0.3 0.2 0.4 0.3 6.3 4.9(28.0) 4.8(26.9) 5.7 5.2(29.9) 5.2(29.9) 6.3 5.5(33.0) 4.9(32.0)
n=100, Predictive only
0.2 0.2 0.4 0.1 13.5 30.8(22.7) 35.7(19.5) 15.0 36.5(26.3) 44.2(22.5) 16.2 31.7(29.7) 42.0(25.5)
0.2 0.2 0.5 0.1 16.1 46.0(25.0) 55.5(20.9) 20.9 55.3(30.0) 67.1(25.0) 25.6 51.4(35.1) 64.4(29.0)
0.2 0.2 0.6 0.1 19.6 60.7(27.3) 73.8(22.4) 27.6 72.6(33.7) 84.6(27.4) 37.1 67.7(40.2) 83.4(32.5)
n=100, Predictive + prognostic
0.4 0.2 0.6 0.1 11.7 26.1(28.8) 32.6(25.5) 13.2 31.2(36.2) 40.4(32.5) 15.1 29.6(43.8) 39.3(39.5)
0.4 0.2 0.7 0.1 14.2 39.2(30.9) 52.7(27.0) 18.3 51.0(40.0) 64.8(35.0) 24.2 47.9(49.0) 62.0(43.0)
0.4 0.2 0.8 0.1 18.3 56.8(33.2) 74.6(28.5) 25.4 69.0(43.8) 85.2(37.5) 36.4 66.3(54.2) 82.7(46.4)
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Table 5: Type I error rate, power (%) and median survival month (in brackets) of the MSGD
and MSFD for evaluating the predictive marker effect under the between-strategy test and
proposed test when the outcome is a survival endpoint.
True hazard Prevalence of M+
Standard Targeted 30% 50% 70%
M+ M- M+ M- MSGD MSFD MSGD MSFD MSGD MSFD
strategy proposed strategy proposed strategy proposed
n=200, No predictive
0.5 0.5 0.25 0.25 14.0 5.0(27.1) 4.8(25.2) 5.2 4.8(27.1) 5.2(26.9) 12.1 4.9(29.0) 5.3(26.9)
n=200, Predictive only
0.5 0.5 0.38 0.75 18.2 42.1(19.2) 51.8(17.3) 16.2 47.6(20.4) 60.0(18.7) 15.5 42.3(21.8) 51.6(19.9)
0.5 0.5 0.25 0.75 27.9 78.6(20.6) 89.0(18.2) 32.1 85.6(23.5) 93.8(20.4) 37.4 78.7(26.6) 88.3(22.8)
0.5 0.5 0.19 0.75 35.1 93.2(21.8) 98.3(19.0) 43.3 97.1(25.9) 98.6(21.6) 52.0 93.6(31.0) 98.0(25.0)
n=200, Predictive + prognostic
0.4 0.5 0.24 0.60 14.5 42.9(22.1) 52.1(20.6) 18.0 48.4(25.2) 58.7(23.0) 22.3 42.8(28.8) 51.3(25.9)
0.4 0.5 0.16 0.60 22.9 79.8(23.8) 89.1(21.6) 33.6 85.9(28.8) 93.8(25.0) 43.8 79.7(35.5) 89.2(29.5)
0.4 0.5 0.12 0.60 29.4 93.6(25.0) 98.2(22.1) 43.9 96.8(31.4) 98.6(26.4) 57.2 93.3(41.0) 98.1(31.9)
n=100, No predictive
0.5 0.5 0.25 0.25 9.2 4.3(27.0) 4.5(25.3) 4.5 5.1(27.1) 4.6(26.6) 9.0 5.0(29.2) 4.6(27.0)
n=100, Predictive only
0.5 0.5 0.38 0.75 9.4 26.8(19.4) 28.0(17.5) 10.5 27.8(20.1) 31.7(18.6) 8.7 25.7(21.8) 26.3(20.0)
0.5 0.5 0.25 0.75 17.9 53.1(20.4) 60.4(18.2) 20.6 62.3(23.6) 66.9(20.6) 23.1 55.5(26.6) 61.3(22.7)
0.5 0.5 0.19 0.75 18.4 70.3(21.8) 77.0(19.0) 26.1 80.5(25.6) 87.1(21.3) 31.5 72.9(31.1) 78.5(24.8)
n=100, Predictive + prognostic
0.4 0.5 0.24 0.60 8.3 28.9(22.2) 29.6(20.4) 12.4 31.4(25.3) 34.5(23.1) 13.2 25.8(28.9) 28.4(25.9)
0.4 0.5 0.16 0.60 14.4 56.9(23.9) 61.1(21.4) 19.2 61.7(28.6) 67.7(24.8) 26.6 52.7(35.3) 62.1(29.2)
0.4 0.5 0.12 0.60 17.8 70.4(25.1) 78.2(22.3) 28.0 78.8(31.4) 86.6(26.4) 32.0 71.1(41.2) 81.5(32.1)
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